Back to Journals Journal of Inflammation Research Volume 17 Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors Authors Rahim K, Shan M, Ul Haq I, Nawaz MN , Maryam S , Alturki MS, Al Khzem AH , Metwally K, Cavalu S, Alqifari SF , Yahya G Received 18 October 2023 Accepted for publication 9 March 2024 Published 23 March 2024 Volume 2024:17 Pages 18971917 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Adam Bachstetter Kashif Rahim, 1 Muhammad Shan, 2 Ihtisham Ul Haq, 3 5 Muhammad Naveed Nawaz, 2 Sajida Maryam, 3, 4 Mansour S Alturki, 6 Abdulaziz H Al Khzem, 6 Kamel Metwally, 7 Simona Cavalu, 8 Saleh F Alqifari, 9 Galal Yahya 10 1 School of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, Peoples Republic of China
Scientific research Cagrilintide subject of active Novo Nordisk clinical program since 2018
Access to a provider, medication & free shipping
The second NPC approval in a week highlights the FDAs commitment to supporting the development of innovative therapies for rare diseases, Janet Maynard, director of the FDAs Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine, said in a statement
